Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling

Nature Medicine

Volumn 11, Issue 8, 2005, Pages 845-852

  Jenkins, Brendan J ^a   Grail, Dianne ^a   Nheu, Thao ^a   Najdovska, Meri ^a   Wang, Bo ^a   Waring, Paul ^b   Inglese, Melissa ^a   McLoughlin, Rachel M ^c   Jones, Simon A ^c   Topley, Nicholas ^c   Baumann, Heinz ^d   Judd, Louise M ^e   Giraud, Andrew S ^e   Boussioutas, Alex ^e   Zhu, Hong Jian ^a   Ernst, Matthias ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; STAT3 PROTEIN;

ACUTE PHASE RESPONSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; GENE MUTATION; HISTOPATHOLOGY; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; SIGNAL TRANSDUCTION; SPLENOMEGALY; STOMACH FUNCTION;

ADENOMA; ANIMALS; CYTOKINE RECEPTOR GP130; HISTOLOGICAL TECHNIQUES; IMMUNOBLOTTING; MICE; MICE, MUTANT STRAINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 23844445451     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1282     Document Type: Article

References (46)

1. Maritano, D. et al. The STAT3 isoforms alpha and beta have unique and specific functions. Nat. Immunol. 5, 401-409 (2004).
2. Levy, D.E. & Lee, C.K. What does Stat3 do? J. Clin. Invest. 109, 1143-1148 (2002).
3. Tebbutt, N.C. et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 8, 1089-1097 (2002).
4. Heinrich, P.C. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1-20 (2003).
5. Croker, B.A. et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4, 540-545 (2003).
6. Lefebvre, O. et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 274, 259-262 (1996).
7. Shi, Y. & Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
8. Nakao, A. et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389, 631-635 (1997).
9. Massague, J., Blain, S.W. & Lo, R.S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309 (2000).
10. Boivin, G.P. et al. Gastric lesions in transforming growth factor beta-1 heterozygous mice. Lab. Invest. 74, 513-518 (1996).
11. Takaku, K. et al. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res. 59, 6113-6117 (1999).
12. Xu, X. et al. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 19, 1868-1874 (2000).
13. Hohenstein, P. et al. Serrated adenomas and mixed polyposis caused by a splice acceptor deletion in the mouse Smad4 gene. Genes Chromosom. Cancer 36, 273-282 (2003).
14. Jenkins, B.J., Roberts, A.W., Najdovska, M., Grail, D. & Ernst, M. The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. Blood 105, 3512-3520 (2005).
15. Takeda, K. et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA 94, 3801-3804 (1997).
16. Judd, L.M. et al. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology 126, 196-207 (2004).
17. Hurst, S.M. et al. II-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14, 705-714 (2001).
18. Peters, M. et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J. Exp. Med. 185, 755-766 (1997).
19. Ernst, M. & Jenkins, B.J. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 20, 23-32 (2004).
20. Bromberg, J.F. et al. Stat3 as an oncogene. Cell 98, 295-303 (1999).
21. Fischer, M. et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15, 142-145 (1997).
22. Ulloa, L., Doody, J. & Massague, J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397, 710-713 (1999).
23. Zhu, H.-J., Iaria, J. & Sizeland, A.M. Smad7 differentially regulates transforming growth factor-β mediated signaling pathways. J. Biol. Chem. 274, 32258-32264 (1999).
24. Kanai, M. et al. Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway. Oncogene 22, 548-554 (2003).
25. Leong, P.L. et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA 100, 4138-4143 (2003).
26. Kanda, N. et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23, 4921-4929 (2004).
27. Lauren, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histological classification. Acta Pathol. Microbiol. Scand. 64, 31-49 (1965).
28. Boussioutas, A. et al. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res. 63, 2569-2577 (2003).
29. Gong, W. et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin. Cancer Res. 11, 1386-1393 (2005).
30. Papadimitrakopoulou, V.A. et al. Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. Clin. Cancer Res. 4, 539-544 (1998).
31. Xie, W. et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 62, 497-505 (2002).
32. Horvath, L.G. et al. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 59, 234-242 (2004).
33. Li, Q.L. et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109, 113-124 (2002).
34. Brenner, O. et al. Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc. Natl. Acad. Sci. USA 101, 16016-16021 (2004).
35. Becker, C. et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21, 491-501 (2004).
36. Monteleone, G. et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108, 601-609 (2001).
37. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6, 583-588 (2000).
38. Howlett, M. et al. Differential regulation of gastric tumor growth by cytokines that signal exclusively through the co-receptor gp130. Gastroenterology (in the press).
39. Bossenmeyer-Pourie, C. et al. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J. Cell Biol. 157, 761-770 (2002).
40. Lerner, L., Henriksen, M.A., Zhang, X. & Darnell, J.E., Jr. STAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene. Genes Dev. 17, 2564-2577 (2003).
41. Darnell, J.E., Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2, 740-749 (2002).
42. Zhu, Y., Richardson, J.A., Parada, L.F. & Graff, J.M. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94, 703-714 (1998).
43. Wang, Y. et al. Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. J. Biol. Chem. 275, 25273-25285 (2000).
44. Stenvers, K.L. et al. Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol. Cell. Biol. 23, 4371-4385 (2003).
45. Brodin, G., Ahgren, A., ten Dijke, P., Heldin, C.H. & Heuchel, R. Efficient TGF-beta induction of the Smad7 gene requires cooperation between AP-1, Sp1, and Smad proteins on the mouse Smad7 promoter. J. Biol. Chem. 275, 29023-29030 (2000).
46. Jenkins, B.J. et al. Imbalanced gp130-dependent signaling in macrophages alters macrophage colony-stimulating factor responsiveness via regulation of c-fms expression. Mol. Cell. Biol. 24, 1453-1463 (2004).